Answers are grounded in this paper and cite their sources.
Background and Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by inflammation, oxidative stress, and mitochondrial dysfunction driven by dysregulated hepatic lipids. As an ER-resident protein, mesencephalic astrocyte-derived neurotrophic factor (MANF) modulates inflammation, oxidative stress, and metabolic homeostasis to mediate hepatic repair. Trilobatin (TLB), a natural food additive with anti-inflammatory and antioxidant activities, remains uncharacterized for its capacity to alleviate MASLD via MANF-dependent regulation of mitochondria-endoplasmic reticulum crosstalk and lipid metabolism. This study aims to investigate the effects of TLB on MASLD and its underlying mechanisms. Experimental Approach: High-fat diet-induced MASLD mice were used to evaluate TLB effects on lipid metabolism, inflammation, oxidative status, and liver pathology. Transcriptomics and untargeted metabolomics were combined to identify core pathways, while molecular docking and molecular dynamics simulations predicted TLB-MANF binding. In palmitate/oleate-challenged lipotoxic HepG2 cells, we detected MANF signaling and MAMs-related IP3R/GRP75/VDAC1, and MANF knockdown validated the mechanism whereby TLB rescues metabolic disturbance and MAMs function. Key Results: TLB attenuates hepatic injury and steatosis in MASLD mice in a dose-dependent manner. Mechanistically, TLB competitively binds to and upregulates MANF, restores MAMs protein expression, suppresses inflammation and oxidative stress, and maintains intracellular calcium homeostasis. It also ameliorates lipid dysregulation, remodels lipid profiles, and improves β-oxidation and mitochondrial function. MANF knockdown abolishes TLB’s protective effects in lipotoxic HepG2 cells. Conclusions and Implications: This study expands the pharmacological profile of TLB and shows that TLB prevents MASLD by regulating MANF signaling and MAMs function to reverse lipid dysregulation, identifying the MANF–MAMs axis as a promising target for MASLD intervention.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: